13 research outputs found
The association of tidal EFL with exercise performance, exacerbations, and death in COPD
Background: Tidal expiratory flow limitation (EFLT) is frequently found in patients with COPD and can be detected by forced oscillations when within-breath reactance of a single-breath is â\u89¥0.28 kPa·s·L-1. The present study explored the association of within-breath reactance measured over multiple breaths and EFLT with 6-minute walk distance (6MWD), exacerbations, and mortality. Methods: In 425 patients, spirometry and forced oscillation technique measurements were obtained on eight occasions over 3 years. 6MWD was assessed at baseline and at the 3-year visit. Respiratory symptoms, exacerbations, and hospitalizations were recorded. A total of 5-year mortality statistics were retrieved retrospectively. We grouped patients according to the mean within-breath reactance (Î\u94(Formula Presented.)), measured over several breaths at baseline, calculated as mean inspiratory-mean expiratory reactance over the sampling period. In addition to the established threshold of EFLT, an upper limit of normal (ULN) was defined using the 97.5th percentile of Î\u94(Formula Presented.) of the healthy controls in the study; 6MWDs were compared according to Î\u94(Formula Presented.), as normal, â\u89¥ ULN < EFLT, or â\u89¥ EFLT. Annual exacerbation rates were analyzed using a negative binomial model in the three groups, supplemented by time to first exacerbation analysis, and dichotomizing patients at the ULN. Results: In patients with COPD and baseline Î\u94(Formula Presented.) below the ULN (0.09 kPa·s·L-1), 6MWD was stable. 6MWD declined significantly in patients with Î\u94(Formula Presented.) â\u89¥ ULN. Worse lung function and more exacerbations were found in patients with COPD with Î\u94(Formula Presented.) â\u89¥ ULN, and patients with Î\u94(Formula Presented.) â\u89¥ ULN had shorter time to first exacerbation and hospitalization. A significantly higher mortality was found in patients with Î\u94(Formula Presented.) â\u89¥ ULN and FEV1.50%. Conclusion: Patients with baseline Î\u94(Formula Presented.) â\u89¥ ULN had a deterioration in exercise performance, more exacerbations, and greater hospitalizations, and, among those with moderate airway obstruction, a higher mortality. Î\u94(Formula Presented.) is a novel independent marker of outcome in COPD
Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques
<p>Abstract</p> <p>Background</p> <p>The reported diagnostic yield from bronchoscopies in patients with lung cancer varies greatly. The optimal combination of sampling techniques has not been finally established.</p> <p>The objectives of this study were to find the predictors of diagnostic yield in bronchoscopy and to evaluate different combinations of sampling techniques.</p> <p>Methods</p> <p>All bronchoscopies performed on suspicion of lung malignancy in 2003 and 2004 were reviewed, and 363 patients with proven malignant lung disease were included in the study. Sampling techniques performed were biopsy, transbronchial needle aspiration (TBNA), brushing, small volume lavage (SVL), and aspiration of fluid from the entire procedure. Logistic regression analyses were adjusted for sex, age, endobronchial visibility, localization (lobe), distance from carina, and tumor size.</p> <p>Results</p> <p>The adjusted odds ratios (OR) with 95% confidence intervals (CI) for a positive diagnostic yield through all procedures were 17.0 (8.5–34.0) for endobronchial lesions, and 2.6 (1.3–5.2) for constriction/compression, compared to non-visible lesions; 3.8 (1.3–10.7) for lesions > 4 cm, 6.7 (2.1–21.8) for lesions 3–4 cm, and 2.5 (0.8–7.9) for lesions 2–3 cm compared with lesions <= 2 cm. The combined diagnostic yield of biopsy and TBNA was 83.7% for endobronchial lesions and 54.2% for the combined group without visible lesions. This was superior to either technique alone, whereas additional brushing, SVL, and aspiration did not significantly increase the diagnostic yield.</p> <p>Conclusion</p> <p>In patients with malignant lung disease, visible lesions and larger tumor size were significant predictors of higher diagnostic yield, after adjustment for sex, age, distance from carina, side and lobe. The combined diagnostic yield of biopsy and TBNA was significant higher than with either technique alone.</p
Clinical information predicting severe obstructive sleep apnea: A cross-sectional study of patients waiting for sleep diagnostics
Drengenes_LaboratoryContamination_DRYAD_fastq
Fastq files generated by Illumina MiSeq sequencing of the bacterial 16S rRNA gene region V3V4 (164 samples, paired-end reads)
Recommended from our members
Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients 'on' or 'off' augmentation therapy.
BackgroundThere is still limited information on systemic inflammation in alpha-1-antitrypsin-deficient (AATD) COPD patients and what effect alpha-1-antitrypsin augmentation therapy and/or exercise might have on circulating inflammatory cytokines. We hypothesized that AATD COPD patients on augmentation therapy (AATD + AUG) would have lower circulating and skeletal muscle inflammatory cytokines compared to AATD COPD patients not receiving augmentation therapy (AATD-AUG) and/or the typical non-AATD (COPD) patient. We also hypothesized that cytokine response to exercise would be lower in AATD + AUG compared to AATD-AUG or COPD subjects.MethodsArterial and femoral venous concentration and skeletal muscle expression of TNFα, IL-6, IL-1β and CRP were measured at rest, during and up to 4-hours after 50% maximal 1-hour knee extensor exercise in all COPD patient groups, including 2 additional groups (i.e. AATD with normal lung function, and healthy age-/activity-matched controls).ResultsCirculating CRP was higher in AATD + AUG (4.7 ± 1.6 mg/dL) and AATD-AUG (3.3 ± 1.2 mg/dL) compared to healthy controls (1.5 ± 0.3 mg/dL, p < 0.05), but lower in AATD compared to non-AATD-COPD patients (6.1 ± 2.6 mg/dL, p < 0.05). TNFα, IL-6 and IL-1β were significantly increased by 1.7-, 1.7-, and 4.7-fold, respectively, in non-AATD COPD compared to AATD COPD (p < 0.05), and 1.3-, 1.7-, and 2.2-fold, respectively, compared to healthy subjects (p < 0.05). Skeletal muscle TNFα was on average 3-4 fold greater in AATD-AUG compared to the other groups (p < 0.05). Exercise showed no effect on these cytokines in any of our patient groups.ConclusionThese data show that AATD COPD patients do not experience the same chronic systemic inflammation and exhibit reduced inflammation compared to non-AATD COPD patients. Augmentation therapy may help to improve muscle efflux of TNFα and reduce muscle TNFα concentration, but showed no effect on IL-6, IL-1β or CRP
Non-Response in Telephone Surveys of Copd Patients Does Not Introduce Bias
We examined the telephone response rates in a 2-year study of patients with COPD to identify factors associated with non-response. A total of 381 patients received monthly telephone calls to assess symptoms and treatment in 2007 and 2008. A total of 9019 calls were made over 24 months, of which 73% were answered. The highest response rate was obtained in February 2007 (81 %), and the lowest in July 2008 (48%). The monthly response rate was lower in the second year of follow up. There were 39 patients (10%) who were less frequent responders, with 10 or fewer responses. Less frequent responders were more likely to be current smokers and have hypoxaemia. The median number of answered calls was 18 (interquartile range 16–20). In bivariate models the median number of responses was significantly lower in subjects with chronic cough. In multivariate models neither demographic nor disease characteristics were significantly associated with non-response. We found less frequent responders to monthly telephone calls to be similar in characteristics to frequent responders. This suggests that non-response does not necessarily introduce bias in telephone surveys of patients with COPD. </jats:p
Drengenes_LaboratoryContamination_DRYAD_Metadata
Metadata file needed to rerun the bioinformatics analyses performed in Laboratory Contamination in Airway Microbiome Studies
Vitamin D, vitamin D binding protein, and longitudinal outcomes in COPD
Background Associations between Vitamin D3 [25(OH)D], vitamin D binding protein (VDBP) and chronic obstructive pulmonary disease (COPD) are previously reported. We aimed to further investigate these associations on longitudinal outcomes.
Methods 426 COPD patients from western Norway, GOLD stage II-IV, aged 40–76, were followed every six-month from 2006 through 2009 with spirometry, bioelectrical impedance measurements and registration of exacerbation frequency. Serum 25(OH)D and VDBP levels were determined at study-entry by high-performance liquid chromatography coupled with mass spectrometry and enzyme immunoassays respectively. Yearly change in lung function and body composition was assessed by generalized estimating equations (GEE), yearly exacerbation rate by negative binomial regression models, and 5 years all-cause mortality by Cox proportional-hazard regression.
Results 1/3 of the patients had vitamin D deficiency (<20ng/mL) and a greater decline in both FEV1 and FVC, compared to patients with normal levels; for FEV1 this difference only reached statistical significance in the 28 patients with the lowest levels (<10ng/mL, p = 0.01). Neither 25(OH)D nor VDBP levels predicted exacerbation rate, change in fat free mass index or risk of death.
Conclusion Severe vitamin D deficiency may affect decline in lung function parameters in COPD. Neither 25(OH)D nor VDBP levels did otherwise predict markers of disease progression
Systemic mannose-binding lectin is not associated with chronic obstructive pulmonary disease
SummaryMannose-binding lectin (MBL) deficiency is associated with increased susceptibility to airways infections and autoimmunity. We examined whether MBL deficiency was more common in COPD patients, and whether MBL deficiency was associated with COPD severity.415 COPD patients and 231 healthy subjects, aged 40–75, were examined in 2006/07. Plasma MBL levels were determined by ELISA. Low or deficient MBL levels were defined as plasma levels below 500ng/mL or 100ng/mL respectively. Logistic regression models determined factors associated with MBL deficiency; with explanatory variables study category, sex, age, smoking, comorbid heart disease, and CRP. For COPD severity, explanatory variables were FEV1, exacerbation history, hypoxia, respiratory symptoms, inhaled steroids, and CRP.18.2% of healthy subjects and 22.2% of patients had MBL levels below 100ng/mL (p=0.23); 42.9% of healthy subjects and 49.6% of patients had levels below 500ng/mL (p=0.10). After adjustment for co-variables, patients had an OR (95% CI) of 1.26 (0.7, 2.2) for having MBL levels below 100ng/mL compared with healthy subjects, and an OR (95% CI) of 1.06 (0.7, 1.7) for having levels below 500ng/mL. Among the COPD patients, none of the disease variables were associated with MBL deficiency.No association was found between MBL deficiency and COPD or COPD severity
